OracleBio will be attending the Annual Immune Checkpoint Inhibitors Europe Summit, which takes place from the 16th to the 18th of November in Munich, Germany.
OracleBio offers a range of digital pathology image analysis services to support pre-clinical and clinical immuno-oncology R&D and have generated data as part of immune checkpoint inhibitor studies. In one recently published study, we performed digital image analysis for quantification of CD8+T-cells in a mouse syngeneic model to demonstrate the potential of a checkpoint inhibitor combination therapy. OracleBio have generated case studies from this research, as well as other immune checkpoint inhibitor studies, and look forward to discussing this in greater detail at ICI Europe 2016.
Returning for the second year, Immune Checkpoint Inhibitors (ICI) Europe 2016 focuses on how to deliver maximum clinical benefit through immune checkpoint monotherapy and combinations. Incorporating insights from industry leaders, the summit will deliver practical learning on what it takes to develop the next generation of ICI drugs, from pathway validation to clinical success. For more information on Immune Checkpoint Inhibitors (ICI) Europe 2016, please click here.
If you would like to learn more about OracleBio’s services, or wish to arrange a time to speak with OracleBio’s Chief Operations Officer John Waller during the conference, please contact us.